SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-KT - Transition reports [Rule 13a-10 or 15d-10]:
SEC Accession No. 0001213900-20-007501
Filing Date
2020-03-26
Accepted
2020-03-26 16:10:15
Documents
70
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 TRANSITION REPORT f10kt2019_relmadatherape.htm 10-KT 1315389
2 CONSENT OF MARCUM LLP f10kt2019ex23-1_relmada.htm EX-23.1 2227
3 CERTIFICATION f10kt2019ex31-1_relmada.htm EX-31.1 7700
4 CERTIFICATION f10kt2019ex31-2_relmada.htm EX-31.2 7765
5 CERTIFICATION f10kt2019ex32-1_relmada.htm EX-32.1 3435
6 CERTIFICATION f10kt2019ex32-2_relmada.htm EX-32.2 3357
  Complete submission text file 0001213900-20-007501.txt   5100378

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE FILE rlmd-20191231.xml EX-101.INS 773933
8 XBRL SCHEMA FILE rlmd-20191231.xsd EX-101.SCH 60074
9 XBRL CALCULATION FILE rlmd-20191231_cal.xml EX-101.CAL 48257
10 XBRL DEFINITION FILE rlmd-20191231_def.xml EX-101.DEF 233376
11 XBRL LABEL FILE rlmd-20191231_lab.xml EX-101.LAB 434104
12 XBRL PRESENTATION FILE rlmd-20191231_pre.xml EX-101.PRE 323815
Mailing Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022
Business Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

IRS No.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-KT | Act: 34 | File No.: 001-39082 | Film No.: 20746246
SIC: 2834 Pharmaceutical Preparations